Go Deep
Neurogene Inc.
Neurogene Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 20,774 | -4.3 | 1.99 | 0.04 | 2,053.24 |
| Oct 2026 | 20,674 | -4.4 | 2.04 | 0.04 | 2,105.94 |
| Oct 2026 | 20,390 | -4.6 | 2.21 | 0.04 | 2,274.32 |
| Oct 2026 | 20,502 | -4.6 | 2.14 | 0.04 | 2,202.12 |
| Oct 2026 | 20,354 | -4.8 | 2.23 | 0.04 | 2,291.71 |
| Oct 2026 | 20,156 | -5.0 | 2.34 | 0.04 | 2,408.34 |
| Oct 2026 | 20,047 | -5.2 | 2.40 | 0.04 | 2,466.70 |
| Oct 2026 | 20,337 | -4.8 | 2.24 | 0.04 | 2,291.81 |
| Oct 2026 | 20,454 | -4.7 | 2.17 | 0.04 | 2,232.12 |
Neurogene Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Profit | -34,488,000.0 | -30,934,000.0 | -24,735,000.0 | -20,953,000.0 |
| EPS | -1.5 | -1.4 | — | -1.0 |
Neurogene Inc. Revenue & Profit: Last 4 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Revenue | 0.0 | 925,000.0 | 0.0 | 0.0 |
| Net Profit | -90,351,000.0 | -75,144,000.0 | -36,317,000.0 | -55,189,000.0 |
| EPS | -4.2 | -4.3 | -73.8 | -37.8 |
Neurogene Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 288,604,000.0 | 335,730,000.0 | 222,573,000.0 | 109,265,000.0 | — |
| Total Liabilities | 23,717,000.0 | 25,355,000.0 | 36,549,000.0 | 255,004,000.0 | — |
| Total Equity | 264,887,000.0 | 310,375,000.0 | 186,024,000.0 | -145,739,000.0 | — |
Owes vs Owns
Neurogene Inc. owed $0.11 for every $1 it owned in Jun 2026, down from $2.33 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.11× | 0.08× | 0.08× | 0.16× | 2.33× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Neurogene Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 93.2%Fixed assets (tangible) 5.4%Other assets 1.3%
How it's funded — Dec 2025
Short-term debt 1.3%Long-term debt 2.5%Payables 0.7%Other liabilities 3.7%Shareholders' equity 91.8%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 269.0 | 312.4 | 197.2 | 82.0 |
| Receivables | 0.5 | 0.6 | 0.6 | 1.0 |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 |
| Fixed assets (tangible) | 15.5 | 18.5 | 21.0 | 24.5 |
| Intangible assets | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 3.7 | 4.2 | 3.9 | 1.7 |
| Liabilities & equity | ||||
| Short-term debt | 3.7 | 4.1 | 2.9 | 0.7 |
| Long-term debt | 7.3 | 10.1 | 13.4 | 4.0 |
| Payables | 2.0 | 1.3 | 2.6 | 0.6 |
| Other liabilities | 10.8 | 9.8 | 17.7 | 249.7 |
| Shareholders' equity | 264.9 | 310.4 | 186.0 | -145.7 |
| Net tangible assets | 264.9 | 310.4 | 186.0 | -145.7 |
Neurogene Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | -77,173,000.0 | -70,603,000.0 | -51,422,000.0 | -52,824,000.0 | — |
| Investing Activities | 14,004,000.0 | -125,261,000.0 | 25,637,000.0 | -2,230,000.0 | — |
| Financing Activities | 30,428,000.0 | 184,071,000.0 | 92,482,000.0 | 66,531,000.0 | — |